Osteoarthritis
(OA) is treated with the intra-articular
injection of steroids such as dexamethasone (DEX) to provide short-term
pain management. However, DEX treatment suffers from rapid joint clearance.
Here, 20 × 10 μm, shape-defined poly(d,l-lactide-co-glycolide)acid microPlates (μPLs) are created and
intra-articularly deposited for the sustained release of DEX. Under
confined conditions, DEX release is projected to persist for several
months, with only ∼20% released in the first month. In a highly
rigorous murine knee overload injury model (post-traumatic osteoarthritis),
a single intra-articular injection of Cy5-μPLs is detected in
the cartilage surface, infrapatellar fat pad/synovium, joint capsule,
and posterior joint space up to 30 days. One intra-articular injection
of DEX-μPL (1 mg kg–1) decreased the expression
of interleukin (IL)-1β, tumor necrosis factor (TNF)-α,
IL-6, and matrix metalloproteinase (MMP)-13 by approximately half
compared to free DEX at 4 weeks post-treatment. DEX-μPL also
reduced load-induced histological changes in the articular cartilage
and synovial tissues relative to saline or free DEX. In sum, the μPLs
provide sustained drug release along with the capability to precisely
control particle geometry and mechanical properties, yielding long-lasting
benefits in overload-induced OA. This work motivates further study
and development of particles that provide combined pharmacological
and mechanical benefits.
A variety of microparticles have been proposed for the sustained and localized delivery of drugs with the objective of increasing therapeutic indexes by circumventing filtering organs and biological barriers. Yet, the geometrical, mechanical, and therapeutic properties of such microparticles cannot be simultaneously and independently tailored during the fabrication process to optimize their performance. In this work, a top-down approach is employed to realize micron-sized polymeric particles, called microplates (μPLs), for the sustained release of therapeutic agents. μPLs are square hydrogel particles, with an edge length of 20 μm and a height of 5 μm, made out of poly(lactic- co-glycolic acid) (PLGA). During the synthesis process, the μPL Young's modulus can be varied from 0.6 to 5 MPa by changing the PLGA amounts from 1 to 7.5 mg, without affecting the μPL geometry while matching the properties of the surrounding tissue. Within the porous μPL matrix, different classes of therapeutic payloads can be incorporated including molecular agents, such as anti-inflammatory dexamethasone (DEX), and nanoparticles containing imaging and therapeutic molecules themselves, thus originating a truly hierarchical platform. As a proof of principle, μPLs are loaded with free DEX and 200 nm spherical polymeric nanoparticles, carrying DEX molecules (DEX-SPNs). Electron and fluorescent confocal microscopy analyses document the uniform distribution and stability of molecular and nanoagents within the μPL matrix. This multiscale, hierarchical microparticle releases DEX for at least 10 days. The inclusion of DEX-SPNs serves to minimize the initial burst release and modulate the diffusion of DEX molecules out of the μPL matrix. The biopharmacological and therapeutic properties together with the fine tuning of geometry and mechanical stiffness make μPLs a unique polymeric depot for the potential treatment of cancer, cardiovascular, and chronic, inflammatory diseases.
Post-traumatic osteoarthritis (PTOA) associated with joint injury triggers a degenerative cycle of matrix destruction and inflammatory signaling, leading to pain and loss of function. Here, prolonged RNA interference (RNAi) of matrix metalloproteinase 13 (MMP13) is tested as a PTOA disease modifying therapy. MMP13 is upregulated in PTOA and degrades the key cartilage structural protein type II collagen. Short interfering RNA (siRNA) loaded nanoparticles (siNPs) were encapsulated in shape-defined poly(lactic-co-glycolic acid) (PLGA) based microPlates (μPLs) to formulate siNP-μPLs that maintained siNPs in the joint significantly longer than delivery of free siNPs. Treatment with siNP-μPLs against MMP13 (siMMP13-μPLs) in a mechanical load-induced mouse model of PTOA maintained potent (65−75%) MMP13 gene expression knockdown and reduced MMP13 protein production in joint tissues throughout a 28-day study. MMP13 silencing reduced PTOA articular cartilage degradation/fibrillation, meniscal deterioration, synovial hyperplasia, osteophytes, and pro-inflammatory gene expression, supporting the therapeutic potential of long-lasting siMMP13-μPL therapy for PTOA.
Fine-tuning loading and release of therapeutic and imaging agents associated with polymeric matrices is a fundamental step in the preclinical development of novel nanomedicines. Here, 1,000 × 400 nm Discoidal Polymeric Nanoconstructs (DPNs) were realized via a top-down, template-based fabrication approach, mixing together poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol)-diacrylate (PEG-DA) chains in a single polymer paste. Two different loading strategies were tested, namely the "direct loading" and the "absorption loading." In the first case, the agent was directly mixed with the polymeric paste to realize DPNs whereas, in the second case, DPNs were first lyophilized and then rehydrated upon exposure to a concentrated aqueous solution of the agent. Under these two loading conditions, the encapsulation efficiencies and release profiles of different agents were systematically assessed. Specifically, six agents were realized by conjugating lipid chains (DSPE) or polymeric chains (PEG) to the near-infrared imaging molecule Cy5 (DSPE-Cy5 A and DSPE-Cy5 B); the chemotherapeutic molecules methotrexate (DSPE-MTX and PEG-MTX) and doxorubicin (LA-DOX and DSPE-DOX). Moderately hydrophobic compounds with low molecular weights (MW) returned encapsulation efficiencies as high as 80% for the absorption loading. In general, direct loading was associated with encapsulation efficiencies lower than 1%. The agent hydrophobicity and MW were shown to be critical also in tailoring the release profiles from DPNs. On triple-negative breast cancer cells (MDA-MB-231), absorption loaded DOX-DPNs showed cytotoxic activities comparable to free DOX but slightly delayed in time. Preliminary in vivo studies demonstrated the high stability of Cy5-DPNs. Collectively, these results demonstrate that the pharmacological properties of DPNs can be finely optimized by changing the loading strategies (direct vs. absorption) and compound attributes (hydrophobicity and molecular weight).
Doxorubicin hydrochloride
(DOX) is currently used to treat orthotropic
and metastatic breast cancer. Because of its side effects, the use
of DOX in cancer patients is sometimes limited; for this reason, several
scientists tried designing drug delivery systems which can improve
drug therapeutic efficacy and decrease its side effects. In this study,
we designed, prepared, and physiochemically characterized nonionic
surfactant vesicles (NSVs) which are obtained by self-assembling different
combinations of hydrophilic (Tween 20) and hydrophobic (Span 20) surfactants,
with cholesterol. DOX was loaded in NSVs using a passive and pH gradient
remote loading procedure, which increased drug loading from ∼1
to ∼45%. NSVs were analyzed in terms of size, shape, size distribution,
zeta potential, long-term stability, entrapment efficiency, and release
kinetics, and nanocarriers having the best physiochemical parameters
were selected for further in vitro tests. NSVs with
and without DOX were stable and showed a sustained drug release up
to 72 h. In vitro studies, with MCF-7 and MDA MB
468 cells, demonstrated that NSVs, containing Span 20, were better
internalized in MCF-7 and MDA MB 468 cells than NSVs with Tween 20.
NSVs increased the anticancer effect of DOX in MCF-7 and MDA MB 468
cells, and this effect is time and dose dependent. In vitro studies using metastatic and nonmetastatic breast cancer cells also
demonstrated that NSVs, containing Span 20, had higher cytotoxicity
than NSVs with Tween 20. The resulting data suggested that DOX-loaded
NSVs could be a promising nanocarrier for the potential treatment
of metastatic breast cancer.
We developed and validated an analytical method based on microextraction packed sorbent (MEPS) and high-performance liquid chromatography (HPLC) coupled to photodiode array (PDA) detector to simultaneously quantify multiple nonsteroidal anti-inflammatory drugs (NSAIDs) and fluoroquinolones (FLQs), which may provide as combination several adverse reactions in nephrology and neurology. The linearity range from LOQs (0.1 μg/mL) to 10 μg/mL, and LODs values were 0.03 μg/mL for both NSAIDs and FLQs. The validation was performed according to international guidelines and the accuracy was tested measuring the precision, intermediate precision and trueness. The drugs stability was tested under different storage conditions (+4 °C and -20 °C) and after three different cycles of freezing and thawing. The method can be a suitable tool to simultaneously detect a possible association of drugs in human biological samples and provide several potentialities for clinical applications, bioequivalence studies, pharmacodynamics and toxicodynamics of different pharmaceutical dosage forms showing NSAIDs and FLQs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.